2022/08/15 更新

写真a

スズキ アツシ
鈴木 淳
SUZUKI Atsushi
所属
医学部附属病院 呼吸器内科 病院助教
職名
病院助教
外部リンク

学位 1

  1. 医学士 ( 2009年4月 ) 

研究キーワード 4

  1. 特発性肺線維症

  2. 患者報告型アウトカム

  3. 間質性肺疾患

  4. 線維芽細胞

現在の研究課題とSDGs 1

  1. 線維性間質性肺疾患の発症予防・治療開発・認知度向上

学歴 2

  1. 名古屋市立大学   医学部

    - 2009年3月

      詳細を見る

    国名: 日本国

  2. 名古屋大学   大学院医学系研究科

    - 2021年3月

所属学協会 6

  1. 米国胸部学会

  2. アジア太平洋呼吸器学会

  3. 日本呼吸器学会

  4. 日本内科学会

  5. 日本呼吸器内視鏡学会

  6. 日本呼吸ケア・リハビリテーション学会

▼全件表示

受賞 6

  1. 2021 Fukuchi Award

    2021年11月   アジア太平洋呼吸器学会   Acute exacerbations of fibrotic interstitial lung diseases

     詳細を見る

    受賞区分:学会誌・学術雑誌による顕彰 

  2. 第27回Pneumo Forum最優秀賞

    2018年10月   線維性間質性肺炎の急性増悪 -Real-world data to support clinical trials-

     詳細を見る

    受賞国:日本国

  3. Top ranked scientific ATS submitted Mini-Oral abstracts from Junior Investigators (APSR-ISRD Joint-Session)

    2018年5月   American Thoracic Society   High-flow nasal cannula oxygen therapy on exercise capacity for fibrosing interstitial lung disease: a proof-of-concept randomized controlled trial

     詳細を見る

    受賞区分:国際学会・会議・シンポジウム等の賞  受賞国:アメリカ合衆国

  4. JRS Yong Investigator

    2018年5月   American Thoracic Society   Acute exacerbations of fibrosing interstitial lung diseases: incidence, risk factors, and outcome

     詳細を見る

    受賞区分:国際学会・会議・シンポジウム等の賞 

  5. 優秀演題賞

    2014年   日本呼吸ケア・リハビリテーション学会   IPF急性増悪におけるNPPVのPEEP効果と予後予測能

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

  6. Young Investigators Award優秀賞

    2013年   日本肺高血圧学会   Lung-dominant CTDにおける肺高血圧の検討

     詳細を見る

    受賞区分:国内学会・会議・シンポジウム等の賞  受賞国:日本国

▼全件表示

 

論文 39

  1. Interstitial lung diseases 招待有り 査読有り 国際共著

    Wijsenbeek M, Suzuki A, Maher TM

    Lancet     2022年8月

     詳細を見る

  2. BMP3b is a novel anti-fibrotic molecule regulated by meflin in lung fibroblasts 査読有り

    Atsushi Suzuki, Koji Sakamoto, Yoshio Nakahara, Atsushi Enomoto, Jun Hino, Akira Ando, Masahide Inoue, Yukihiro Shiraki, Norihito Omote, Masahiro Kusaka, Jun Fukihara, and Naozumi Hashimoto

    American Journal of Respiratory Cell and Molecular Biology     2022年6月

     詳細を見る

    担当区分:筆頭著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1165/rcmb.2021-0484OC

  3. COVID-19-Triggered Acute Exacerbation of IPF, an Underdiagnosed Clinical Entity With Two-Peaked Respiratory Failure: A Case Report and Literature Review

    Goto Y., Sakamoto K., Fukihara J., Suzuki A., Omote N., Ando A., Shindo Y., Hashimoto N.

    Frontiers in Medicine   9 巻   頁: 815924   2022年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:Frontiers in Medicine  

    Because severe coronavirus disease 2019 (COVID-19) affects the respiratory system and develops into respiratory failure, patients with pre-existing chronic lung disorders, such as idiopathic pulmonary fibrosis (IPF), are thought to be at high risk of death. Patients with IPF often suffer from a lethal complication, acute exacerbation (AE), a significant part of which is assumed to be triggered by respiratory viral infection. However, whether mild to moderate COVID-19 can trigger AE in patients with IPF remains unknown. This is the case report of a 60-year-old man with a 4-year history of IPF who successfully recovered from moderate COVID-19 but subsequently developed more severe respiratory failure, which was considered to be a COVID-19-triggered acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). It is important to be aware of the risk of AE-IPF after COVID-19 and to properly manage this deadly complication of IPF. Recent literature reporting cases with chronic interstitial lung diseases which developed respiratory failure by complications with COVID-19 is also reviewed and discussed.

    DOI: 10.3389/fmed.2022.815924

    Scopus

    PubMed

  4. Successful Treatment with High-dose Steroids for Acute Exacerbation of Idiopathic Pulmonary Fibrosis Triggered by COVID-19

    Omote N., Kanemitsu Y., Inoue T., Yonezawa T., Ichihashi T., Shindo Y., Sakamoto K., Ando A., Suzuki A., Niimi A., Ito S., Imaizumi K., Hashimoto N.

      61 巻 ( 2 ) 頁: 233 - 236   2022年1月

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本内科学会  

    We herein report a case of acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) triggered by COVID-19. An 87-year-old woman tested positive for COVID-19 on a polymerase chain reaction test, and computed tomography revealed ground-glass opacity (GGO) superimposed on a background pattern consistent with usual interstitial pneumonia. Considering these data, we diagnosed her with AE-IPF. She experienced worsening of dyspnea and expansion of the GGO. Therefore, we introduced high-dose steroids (methylprednisolone 250 mg/day for 3 days). After the treatment, the pulmonary infiltrates improved. She was discharged from our hospital without severe disability. High-dose steroids can be a viable treatment option for AE-IPF triggered by COVID-19.

    DOI: 10.2169/internalmedicine.8163-21

    Scopus

    PubMed

    CiNii Research

  5. The prognostic value of the COPD Assessment Test in fibrotic interstitial lung disease

    Matsuda Toshiaki, Kondoh Yasuhiro, Furukawa Taiki, Suzuki Atsushi, Takei Reoto, Sasano Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Kataoka Kensuke, Kimura Tomoki

    RESPIRATORY INVESTIGATION   60 巻 ( 1 ) 頁: 99 - 107   2022年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respiratory Investigation  

    Background: The COPD Assessment Test (CAT) has been studied as a measure of health status in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease associated with connective tissue disease. However, its prognostic value is unknown. The present study explored the association between CAT score and mortality in fibrotic interstitial lung disease (FILD), including IPF and other forms of ILD. Methods: We retrospectively analyzed 501 consecutive patients with FILD who underwent clinical assessment, including pulmonary function test and CAT. The association between CAT score and 3-year mortality was assessed using Cox proportional hazard analysis, Kaplan–Meier plots, and the log-rank test for trend. To handle missing data, the imputed method was used. Results: The patients’ median age was 68 years, and 320 were male (63.9%). Regarding CAT severity, 203 patients had a low impact level (score <10), 195 had a medium level (10–20), 80 had a high level (21–30), and 23 had a very high level (31–40). During the 3-year study period, 118 patients died. After adjusting for age, sex, forced vital capacity, diffusion capacity for carbon monoxide, IPF diagnosis, and usual interstitial pneumonia pattern on high-resolution computed tomography, the CAT score was significantly associated with 3-year mortality (hazard ratio in increments of 10 points: 1.458, 95% confidence interval 1.161–1.830; p < 0.001). In addition, patients with high and very high impact levels had twofold and threefold higher mortality risk than those with low levels, respectively. Conclusion: The CAT has prognostic value in FILD.

    DOI: 10.1016/j.resinv.2021.07.007

    Web of Science

    Scopus

    PubMed

  6. Size and surface modification of silica nanoparticles affect the severity of lung toxicity by modulating endosomal ROS generation in macrophages

    Inoue M., Sakamoto K., Suzuki A., Nakai S., Ando A., Shiraki Y., Nakahara Y., Omura M., Enomoto A., Nakase I., Sawada M., Hashimoto N.

    Particle and Fibre Toxicology   18 巻 ( 1 ) 頁: 21   2021年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:Particle and Fibre Toxicology  

    Background: As the application of silica nanomaterials continues to expand, increasing chances of its exposure to the human body and potential harm are anticipated. Although the toxicity of silica nanomaterials is assumed to be affected by their physio-chemical properties, including size and surface functionalization, its molecular mechanisms remain unclear. We hypothesized that analysis of intracellular localization of the particles and subsequent intracellular signaling could reveal a novel determinant of inflammatory response against silica particles with different physico-chemical properties. Results: We employed a murine intratracheal instillation model of amorphous silica nanoparticles (NPs) exposure to compare their in vivo toxicities in the respiratory system. Pristine silica-NPs of 50 nm diameters (50 nm-plain) induced airway-centered lung injury with marked neutrophilic infiltration. By contrast, instillation of pristine silica particles of a larger diameter (3 μm; 3 μm-plain) significantly reduced the severity of lung injury and neutrophilic infiltration, possibly through attenuated induction of neutrophil chemotactic chemokines including MIP2. Ex vivo analysis of alveolar macrophages as well as in vitro assessment using RAW264.7 cells revealed a remarkably lower cellular uptake of 3 μm-plain particles compared with 50 nm-plain, which is assumed to be the underlying mechanism of attenuated immune response. The severity of lung injury and neutrophilic infiltration was also significantly reduced after intratracheal instillation of silica NPs with an amine surface modification (50 nm-NH2) when compared with 50 nm-plain. Despite unchanged efficacy in cellular uptake, treatment with 50 nm-NH2 induced a significantly attenuated immune response in RAW264.7 cells. Assessment of intracellular redox signaling revealed increased reactive oxygen species (ROS) in endosomal compartments of RAW264.7 cells treated with 50 nm-plain when compared with vehicle-treated control. In contrast, augmentation of endosomal ROS signals in cells treated with 50 nm-NH2 was significantly lower. Moreover, selective inhibition of NADPH oxidase 2 (NOX2) was sufficient to inhibit endosomal ROS bursts and induction of chemokine expressions in cells treated with silica NPs, suggesting the central role of endosomal ROS generated by NOX2 in the regulation of the inflammatory response in macrophages that endocytosed silica NPs. Conclusions: Our murine model suggested that the pulmonary toxicity of silica NPs depended on their physico-chemical properties through distinct mechanisms. Cellular uptake of larger particles by macrophages decreased, while surface amine modification modulated endosomal ROS signaling via NOX2, both of which are assumed to be involved in mitigating immune response in macrophages and resulting lung injury.

    DOI: 10.1186/s12989-021-00415-0

    Scopus

    PubMed

  7. Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?

    Aronson K.I., Suzuki A.

    Frontiers in Medicine   8 巻   頁: 745908   2021年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:Frontiers in Medicine  

    Health-Related Quality of Life (HRQOL) is increasingly viewed as an important patient-centered outcome by leading health organizations, clinicians, and patients alike. This is especially true in the interstitial lung disease community where patients often struggle with progressive and debilitating disease with few therapeutic options. In order to test the effectiveness of new pharmacologic therapies and non-pharmacologic interventions globally in ILD, this will require expansion of clinical research studies to a multinational level and HRQOL will be an important endpoint to many. In order to successfully expand trials across multiple nations and compare the results of studies between different communities we must recognize that there are differences in the concepts of HRQOL across the world and have strategies to address these differences. In this review, we will describe the different global influences on HRQOL both generally and in the context of ILD, discuss the processes of linguistic translation and cross-cultural adaptation of HRQOL Patient Reported Outcome Measures (PROMs), and highlight the gaps and opportunities for improving HRQOL measurement in ILD across the world.

    DOI: 10.3389/fmed.2021.745908

    Scopus

    PubMed

  8. Patient-centered outcomes research in interstitial lung disease: An official american thoracic society research statement

    Aronson K.I., Swigris J.J., Bajwah S., Bianchi P., Corte T.J., Danoff S.K., Lee J.S., Lindell K.O., Maher T., Martinez F.J., Meek P.M., Raghu G., Rouland G., Rudell R., Russell A.M., Ryerson C.J., Safford M.M., Sheth J.S., Suzuki A., Wijsenbeek M.S.

    American Journal of Respiratory and Critical Care Medicine   204 巻 ( 2 ) 頁: E3 - E23   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:American Journal of Respiratory and Critical Care Medicine  

    Background: In the past two decades, many advances have been made to our understanding of interstitial lung disease (ILD) and the way we approach its treatment. Despite this, many questions remain unanswered, particularly those related to how the disease and its therapies impact outcomes that are most important to patients. There is currently a lack of guidance on how to best define and incorporate these patient-centered outcomes in ILD research. Objectives: To summarize the current state of patient-centered outcomes research in ILD, identify gaps in knowledge and research, and highlight opportunities and methods for future patient-centered research agendas in ILD. Methods: An international interdisciplinary group of experts was assembled. The group identified top patient-centered outcomes in ILD, reviewed available literature for each outcome, highlighted important discoveries and knowledge gaps, and formulated research recommendations. Results: The committee identified seven themes around patient-centered outcomes as the focus of the statement. After a review of the literature and expert committee discussion, we developed 28 research recommendations. Conclusions: Patient-centered outcomes are key to ascertaining whether and how ILD and interventions used to treat it affect the way patients feel and function in their daily lives. Ample opportunities exist to conduct additional work dedicated to elevating and incorporating patient-centered outcomes in ILD research.

    DOI: 10.1164/rccm.202105-1193ST

    Scopus

    PubMed

  9. The effect of pirfenidone on the prescription of antibiotics and antitussive drugs in patients with idiopathic pulmonary fibrosis: a post-hoc exploratory analysis of phase III clinical trial.

    Suzuki A, Sakaguchi H, Sakamoto K, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Sugiyama Y, Kudoh S, Nukiwa T, Miyazawa S, Kondoh Y

    Chest     2021年6月

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.chest.2021.05.058

    PubMed

  10. Fibroblasts positive for meflin have anti-fibrotic property in pulmonary fibrosis.

    Nakahara Y, Hashimoto N, Sakamoto K, Enomoto A, Adams TS, Yokoi T, Omote N, Poli S, Ando A, Wakahara K, Suzuki A, Inoue M, Hara A, Mizutani Y, Imaizumi K, Kawabe T, Rosas IO, Takahashi M, Kaminski N, Hasegawa Y

    The European respiratory journal     2021年5月

     詳細を見る

    記述言語:英語  

    DOI: 10.1183/13993003.03397-2020

    PubMed

  11. Serum mitochondrial DNA predicts the risk of acute exacerbation and progression of idiopathic pulmonary fibrosis

    Sakamoto Koji, Furukawa Taiki, Yamano Yasuhiko, Kataoka Kensuke, Teramachi Ryo, Walia Anjali, Suzuki Atsushi, Inoue Masahide, Nakahara Yoshio, Ryu Changwan, Hashimoto Naozumi, Kondoh Yasuhiro

    EUROPEAN RESPIRATORY JOURNAL   57 巻 ( 1 )   2021年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:European Respiratory Journal  

    DOI: 10.1183/13993003.01346-2020

    Web of Science

    Scopus

    PubMed

  12. Acute exacerbations of fibrotic interstitial lung diseases

    Suzuki Atsushi, Kondoh Yasuhiro, Brown Kevin K., Johkoh Takeshi, Kataoka Kensuke, Fukuoka Junya, Kimura Tomoki, Matsuda Toshiaki, Yokoyama Toshiki, Fukihara Jun, Ando Masahiko, Tanaka Tomonori, Hashimoto Naozumi, Sakamoto Koji, Hasegawa Yoshinori

    RESPIROLOGY   25 巻 ( 5 ) 頁: 525 - 534   2020年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respirology  

    DOI: 10.1111/resp.13682

    Web of Science

    Scopus

    PubMed

  13. Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?

    Fukihara Jun, Kondoh Yasuhiro, Brown Kevin K., Kimura Tomoki, Kataoka Kensuke, Matsuda Toshiaki, Yamano Yasuhiko, Suzuki Atsushi, Furukawa Taiki, Sumikawa Hiromitsu, Takahashi Osamu, Johkoh Takeshi, Tanaka Tomonori, Fukuoka Junya, Hashimoto Naozumi, Hasegawa Yoshinori

    EUROPEAN RESPIRATORY JOURNAL   55 巻 ( 4 )   2020年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:European Respiratory Journal  

    DOI: 10.1183/13993003.02465-2018

    Web of Science

    Scopus

    PubMed

  14. The impact of high-flow nasal cannula oxygen therapy on exercise capacity in fibrotic interstitial lung disease: a proof-of-concept randomized controlled crossover trial

    Suzuki Atsushi, Ando Masahiko, Kimura Tomoki, Kataoka Kensuke, Yokoyama Toshiki, Shiroshita Eiichi, Kondoh Yasuhiro

    BMC PULMONARY MEDICINE   20 巻 ( 1 ) 頁: 51   2020年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:BMC Pulmonary Medicine  

    DOI: 10.1186/s12890-020-1093-2

    Web of Science

    Scopus

    PubMed

  15. The Role of Meflin Expression in Fibroblasts During Development of Pulmonary Fibrosis

    Hashimoto N., Nakahara Y., Sakamoto K., Enomoto A., Yokoi T., Suzuki A., Inoue M., Wakahara K., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   201 巻   2020年

     詳細を見る

    記述言語:日本語  

    Web of Science

  16. Acute Exacerbation of Pleuroparenchymal Fibroelastosis Secondary to Allogenic Hematopoietic Stem Cell Transplantation

    Murakami Yasushi, Sakamoto Koji, Okumura Yuki, Suzuki Atsushi, Mii Shinji, Sato Mitsuo, Yokoi Toyoharu, Hashimoto Naozumi, Hasegawa Yoshinori

    Internal Medicine   59 巻 ( 21 ) 頁: 2737 - 2743   2020年

     詳細を見る

    記述言語:英語   出版者・発行元:一般社団法人 日本内科学会  

    <p>In this article, we report a case with pleuroparenchymal fibroelastosis (PPFE) following hematopoietic stem cell transplantation (HSCT) that developed acute respiratory failure with new bilateral ground glass opacity, which could not be explained by either a pulmonary infection, drug toxicity or extraparenchymal causes. Although combination therapy with multiple immunosuppressants was transiently effective, the patient died from a recurrent exacerbation. Autopsied lungs demonstrated diffuse alveolar damage superimposed on PPFE. There was no evidence of any coexisting interstitial pneumonia with the usual interstitial pneumonia (UIP) pattern. Our case suggests that acute exacerbation can occur in patients with post-HSCT PPFE, even when a coexisting UIP pattern is absent. </p>

    DOI: 10.2169/internalmedicine.4995-20

    Web of Science

    Scopus

    PubMed

  17. Silica Nanoparticle Induced Lung Injury in Mice: Dissecting Relative Contribution of Its Size and Surface Modification

    Inoue M., Sakamoto K., Suzuki A., Nakahara Y., Hashimoto N., Hasegawa Y., Sawada M.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   201 巻   2020年

     詳細を見る

    記述言語:日本語  

    Web of Science

  18. Pirfenidone Delays the Prescription of Concomitant Drugs in Patients with Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Japanese Phase III Clinical Trial

    Suzuki A., Sakaguchi H., Ebina M., Azuma A., Ogura T., Taguchi Y., Suga M., Takahashi H., Sugiyama Y., Kudoh S., Nukiwa T., Miyazawa S., Sakamoto K., Kondoh Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   201 巻   2020年

     詳細を見る

    記述言語:日本語  

    Web of Science

  19. Increased Circulating Mitochondrial DNA Content Predicts Fatal Complication and Worse Prognosis in Idiopathic Pulmonary Fibrosis

    Sakamoto K., Furukawa T., Yamano Y., Teramachi R., Suzuki A., Nakahara Y., Inoue M., Kataoka K., Hashimoto N., Kondoh Y., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   201 巻   2020年

     詳細を見る

    記述言語:日本語  

    Web of Science

  20. Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation

    Oi Hajime, Suzuki Atsushi, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Suzuki Yasuhiko, Kimura Tomoki, Kondoh Yasuhiro

    RESPIRATORY MEDICINE CASE REPORTS   31 巻   頁: 101157   2020年

     詳細を見る

    記述言語:日本語   出版者・発行元:Respiratory Medicine Case Reports  

    Drug-induced lung injury (DLI) has become more common because of the increasing number of therapeutic agents in use. Mesalazine, also known as 5-aminosalicylic acid (5-ASA), is one of the key drugs for the treatment of ulcerative colitis (UC). Although mesalazine-induced lung injury has been previously reported, few cases have included severe respiratory failure. In this report, we present a case of mesalazine-induced lung injury with severe respiratory failure, which was improved by discontinuation of mesalazine and introduction of corticosteroid therapy and ventilation support with non-invasive positive pressure ventilation (NPPV). We also review the previous literature on mesalazine-induced lung injury.

    DOI: 10.1016/j.rmcr.2020.101157

    Web of Science

    Scopus

    PubMed

  21. The new-defined mesenchymal stromal/stem cell marker has a protective role in the development of acute lung injury

    Nakahara Yoshio, Hashimoto Naozumi, Sakamoto Koji, Ando Akira, Inoue Masahide, Suzuki Atsushi, Enomoto Atsushi, Hasegawa Yoshinori

    EUROPEAN RESPIRATORY JOURNAL   54 巻   2019年9月

     詳細を見る

  22. Performance of the COPD Assessment Test in patients with connective tissue disease-associated interstitial lung disease

    Suzuki Atsushi, Kondoh Yasuhiro, Swigris Jeffrey James, Matsuda Toshiaki, Kimura Tomoki, Kataoka Kensuke, Ando Masahiko, Hashimoto Naozumi, Sakamoto Koji, Hasegawa Yoshinori

    RESPIRATORY MEDICINE   150 巻   頁: 15 - 20   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respiratory Medicine  

    DOI: 10.1016/j.rmed.2019.01.017

    Web of Science

    Scopus

    PubMed

  23. Recurrent Acute Exacerbations of Fibrotic Interstitial Lung Diseases

    Suzuki A., Kondoh Y., Brown K. K., Kimura T., Kataoka K., Matsuda T., Yokoyama T., Ando M., Hashimoto N., Sakamoto K., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   199 巻   2019年

     詳細を見る

    記述言語:日本語  

    Web of Science

  24. Performance of the St George's Respiratory Questionnaire in patients with connective tissue disease-associated interstitial lung disease

    Suzuki Atsushi, Kondoh Yasuhiro, Swigris Jeffrey J., Ando Masahiko, Kimura Tomoki, Kataoka Kensuke, Yamano Yasuhiko, Furukawa Taiki, Numata Mari, Sakamoto Koji, Hasegawa Yoshinori

    RESPIROLOGY   23 巻 ( 9 ) 頁: 851 - 859   2018年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respirology  

    DOI: 10.1111/resp.13293

    Web of Science

    Scopus

    PubMed

  25. Prognostic evaluation by oxygenation with positive end-expiratory pressure in acute exacerbation of idiopathic pulmonary fibrosis: A retrospective cohort study

    Suzuki Atsushi, Taniguchi Hiroyuki, Ando Masahiko, Kondoh Yasuhiro, Kimura Tomoki, Kataoka Kensuke, Matsuda Toshiaki, Yokoyama Toshiki, Sakamoto Koji, Hasegawa Yoshinori

    CLINICAL RESPIRATORY JOURNAL   12 巻 ( 3 ) 頁: 895 - 903   2018年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:Clinical Respiratory Journal  

    DOI: 10.1111/crj.12602

    Web of Science

    Scopus

    PubMed

  26. Acute exacerbation of idiopathic pulmonary fibrosis triggered by Aspergillus empyema

    Suzuki A.

    Respiratory Medicine Case Reports   23 巻   頁: 103 - 106   2018年

     詳細を見る

    記述言語:日本語   出版者・発行元:Respiratory Medicine Case Reports  

    DOI: 10.1016/j.rmcr.2018.01.004

    Scopus

    PubMed

  27. High-Flow Nasal Cannula Oxygen Therapy on Exercise Capacity for Fibrosing Interstitial Lung Disease: A Proof-of-Concept Randomized Controlled Trial

    Suzuki A., Ando M., Kimura T., Kataoka K., Yokoyama T., Shiroshita E., Kondoh Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   197 巻   2018年

     詳細を見る

    記述言語:日本語  

    Web of Science

  28. Acute Exacerbations of Fibrosing Interstitial Lung Diseases: Incidence, Risk Factors, and Outcome

    Suzuki A., Kondoh Y., Brown K. K., Kimura T., Kataoka K., Matsuda T., Yokoyama T., Ando M., Hashimoto N., Sakamoto K., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   197 巻   2018年

     詳細を見る

    記述言語:日本語  

    Web of Science

  29. CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis

    Yagi Mitsuaki, Taniguchi Hiroyuki, Kondoh Yasuhiro, Ando Masahiko, Kimura Tomoki, Kataoka Kensuke, Furukawa Taiki, Suzuki Atsushi, Johkoh Takeshi, Hasegawa Yoshinori

    RESPIROLOGY   22 巻 ( 7 ) 頁: 1393 - 1399   2017年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respirology  

    DOI: 10.1111/resp.13066

    Web of Science

    Scopus

    PubMed

  30. Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction

    Teramachi Ryo, Taniguchi Hiroyuki, Kondoh Yasuhiro, Ando Masahiko, Kimura Tomoki, Kataoka Kensuke, Suzuki Atsushi, Furukawa Taiki, Sakamoto Koji, Hasegawa Yoshinori

    RESPIROLOGY   22 巻 ( 5 ) 頁: 986 - 990   2017年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respirology  

    DOI: 10.1111/resp.12986

    Web of Science

    Scopus

    PubMed

  31. Recent advances in connective tissue disease related interstitial lung disease.

    Suzuki A, Kondoh Y, Fischer A

    Expert review of respiratory medicine   11 巻 ( 7 ) 頁: 591 - 603   2017年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.1080/17476348.2017.1335600

    PubMed

  32. COPD Assessment Test for measurement of health status in patients with idiopathic pulmonary fibrosis: A cross-sectional study

    Matsuda Toshiaki, Taniguchi Hiroyuki, Ando Masahiko, Kondoh Yasuhiro, Kimura Tomoki, Kataoka Kensuke, Sakamoto Koji, Suzuki Atsushi, Furukawa Taiki, Hasegawa Yoshinori

    RESPIROLOGY   22 巻 ( 4 ) 頁: 721 - 727   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respirology  

    DOI: 10.1111/resp.12936

    Web of Science

    Scopus

    PubMed

  33. Soluble thrombomodulin in bronchoalveolar lavage fluid is an independent predictor of severe drug-induced lung injury

    Suzuki Atsushi, Taniguchi Hiroyuki, Kondoh Yasuhiro, Ando Masahiko, Watanabe Naohiro, Kimura Tomoki, Kataoka Kensuke, Yokoyama Toshiki, Sakamoto Koji, Hasegawa Yoshinori

    RESPIROLOGY   22 巻 ( 4 ) 頁: 744 - 749   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respirology  

    DOI: 10.1111/resp.12965

    Web of Science

    Scopus

    PubMed

  34. The clinical impact of major comorbidities on idiopathic pulmonary fibrosis

    Suzuki Atsushi, Kondoh Yasuhiro

    RESPIRATORY INVESTIGATION   55 巻 ( 2 ) 頁: 94 - 103   2017年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:Respiratory Investigation  

    Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating disease with a median survival time of 2–3 years after diagnosis. Patients with IPF exhibit distinct patterns of disease progression, and some patients display a more rapidly progressive clinical course. The clinical course of IPF may also include periods of acute deterioration, which are termed acute exacerbations. Patients with IPF frequently experience various comorbidities, such as pulmonary infection, emphysema, pulmonary hypertension, lung cancer, gastroesophageal reflux, cardiovascular disease, diabetes mellitus, and obstructive sleep apnea. A previous age- and sex-matched study showed that IPF itself was an independent risk factor for these comorbidities. Other studies have demonstrated that these comorbidities are associated with disease progression and mortality in IPF. These variations in the clinical course and comorbidities have affected the researchers’ and physicians’ understanding of IPF. Therefore, better identification and understanding of these variations may be helpful when making decisions regarding therapeutic interventions. Furthermore, the identification and treatment of comorbidities may have a clinically significant impact on patient survival. Future studies should use well-established definitions for distinct progression patterns and comorbid conditions to obtain greater insights into the pathogenesis and treatment of IPF.

    DOI: 10.1016/j.resinv.2016.11.004

    Web of Science

    Scopus

    PubMed

  35. Performance Of The Saint George's Respiratory Questionnaire (sgrq) In Patients With Connective Tissue Disease-Associated Interstitial Lung Disease (ctd-Ild)

    Suzuki A., Taniguchi H., Kondoh Y., Swigris J. J., Yamano Y., Furukawa T., Numata-Nakamura M., Sakamoto K., Ando M., Hasegawa Y.

    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE   195 巻   2017年

     詳細を見る

    記述言語:日本語  

    Web of Science

  36. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study

    Takahashi Kota, Taniguchi Hiroyuki, Ando Masahiko, Sakamoto Koji, Kondoh Yasuhiro, Watanabe Naohiro, Kimura Tomoki, Kataoka Kensuke, Suzuki Atsushi, Ito Satoru, Hasegawa Yoshinori

    BMC PULMONARY MEDICINE   16 巻 ( 1 ) 頁: 55   2016年4月

     詳細を見る

  37. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.

    Suzuki A, Kondoh Y, Taniguchi H, Tabata K, Kimura T, Kataoka K, Ono K, Hashisako M, Fukuoka J

    Respiratory medicine case reports   19 巻   頁: 5 - 8   2016年

     詳細を見る

    記述言語:英語  

    DOI: 10.1016/j.rmcr.2016.05.008

    PubMed

  38. PaO2/FiO(2) with low PEEP using NPPV is a significant predictor on survival in acute exacerbation of idiopathic pulmonary fibrosis

    Suzuki Atsushi, Taniguchi Hiroyuki, Kondoh Yasuhiro, Kimura Tomoki, Kataoka Kensuke, Matsuda Toshiaki, Yokoyama Toshiki, Ando Masahiko

    EUROPEAN RESPIRATORY JOURNAL   46 巻   2015年9月

     詳細を見る

  39. Significance of Pulmonary Arterial Pressure as a Prognostic Indicator in Lung-Dominant Connective Tissue Disease

    Suzuki Atsushi, Taniguchi Hiroyuki, Watanabe Naohiro, Kondoh Yasuhiro, Kimura Tomoki, Kataoka Kensuke, Matsuda Toshiaki, Yokoyama Toshiki, Sakamoto Koji, Nishiyama Osamu, Hasegawa Yoshinori

    PLOS ONE   9 巻 ( 9 )   2014年9月

     詳細を見る

    記述言語:日本語  

    DOI: 10.1371/journal.pone.0108339

    Web of Science

▼全件表示

書籍等出版物 5

  1. 間質性肺疾患診療マニュアル 改訂第3版

    鈴木淳, 近藤康博( 担当: 分担執筆 ,  範囲: 治験中の抗線維化薬)

    南江堂  2020年6月  ( ISBN:9784524248957

  2. みんなの呼吸器 Respica(レスピカ) 2019年4月号(第17巻4号)

    鈴木淳( 担当: 分担執筆 ,  範囲: 【間質性肺炎の呼吸管理とケア コンプリートガイド】 Part. 3 回復期〜慢性安定期の呼吸管理とケア (1) 急性期回復後の多面的評価)

    メディカ出版  2019年7月  ( ISBN:4840467587

  3. みんなの呼吸器 Respica(レスピカ) 2019年2月号(第17巻2号)

    鈴木淳( 担当: 分担執筆 ,  範囲: 安定期も増悪期も、ココがわかれば上手くいく COPDのパーフェクト呼吸管理】 Part.2 治療 (4) 基本の吸入薬)

    メディカ出版  2019年3月  ( ISBN:4840467560

  4. 気管支肺胞洗浄「BAL」法の手引き 改定第3版

    近藤康博, 鈴木淳, 富貴原淳( 担当: 分担執筆 ,  範囲: III BALの治療応用】 B. BALの治療応用(肺胞蛋白症以外))

    克誠堂出版  2017年10月  ( ISBN:9784771904897

  5. 敗血症治療 : 一刻を争う現場での疑問に答える

    鈴木淳, 長谷川隆一( 担当: 分担執筆 ,  範囲: 院内感染予防のために選択的消化管除菌(selective decontamination of the digestive tract:SDD)は行うべきか?)

    羊土社  2014年3月  ( ISBN:9784758112017

MISC 3

  1. 肺線維症の慢性期管理(併存症の管理を含めて)

    森裕太, 鈴木淳, 近藤康博  

    呼吸器内科32 巻 ( 3 ) 頁: 259 - 266   2017年9月

  2. 【『NPPV(非侵襲的陽圧換気)ガイドライン第2版』をめぐって 】間質性肺炎に対するNPPV 招待有り

    鈴木淳, 谷口博之  

    日本胸部臨床75 巻 ( 6 ) 頁: 600 - 606   2016年6月

     詳細を見る

    担当区分:筆頭著者  

  3. 【体腔液の臨床検査】 気管支肺胞洗浄液 招待有り

    鈴木淳, 近藤康博  

    臨床検査60 巻 ( 5 ) 頁: 498 - 502   2016年5月

     詳細を見る

    担当区分:筆頭著者  

講演・口頭発表等 1

  1. 線維性間質性肺疾患における急性増悪 招待有り

    鈴木淳

    第1回日本びまん性肺疾患研究会  2021年10月2日 

     詳細を見る

    記述言語:日本語   会議種別:シンポジウム・ワークショップ パネル(指名)